9 research outputs found
SOAT1: a suitable target for therapy in high-grade astrocytic glioma?
Targeting molecular alterations as an effective treatment for isocitrate dehydrogenase-wildtype glioblastoma (GBM) patients has not yet been established. Sterol-O-Acyl Transferase 1 (SOAT1), a key enzyme in the conversion of endoplasmic reticulum cholesterol to esters for storage in lipid droplets (LD), serves as a target for the orphan drug mitotane to treat adrenocortical carcinoma. Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in these tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP, Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as Oil Red O staining. To a small extent SOAT1 was expressed by tumor cells in both tumor entities. In contrast, strong expression was observed in glioma-associated macrophages. Triple immunofluorescence labeling revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively. Furthermore, a notable difference in the amount of LD between GBM and HGA was observed. Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and invasiveness. In addition, the high expression in cells related to neuroinflammation could be beneficial for a concomitant suppression of protumoral microglia/macrophages
SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?
Targeting molecular alterations as an effective treatment for isocitrate dehydrogenasewildtype
glioblastoma (GBM) patients has not yet been established. Sterol-O-Acyl Transferase 1
(SOAT1), a key enzyme in the conversion of endoplasmic reticulum cholesterol to esters for storage in
lipid droplets (LD), serves as a target for the orphan drug mitotane to treat adrenocortical carcinoma.
Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM
and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in
these tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP,
Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as Oil Red O staining. To
a small extent SOAT1 was expressed by tumor cells in both tumor entities. In contrast, strong
expression was observed in glioma-associated macrophages. Triple immunofluorescence labeling
revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively.
Furthermore, a notable difference in the amount of LD between GBM and HGA was observed.
Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and
invasiveness. In addition, the high expression in cells related to neuroinflammation could be beneficial
for a concomitant suppression of protumoral microglia/macrophages
Purification and functional characterization of the SMN-complex in Drosophila melanogaster
Die Zusammenlageurng spleißosomaler UsnRNPs erfolgt beim Menschen und anderen Vertebraten durch den makromolekularen SMN-Komplex. Dieser besteht aus insgesamt neun Proteinen, genannt SMN und Gemin2-8. In dieser Arbeit wurde die Evolution dieser molekularen Maschine untersucht. Dazu wurden die Genome mehrerer Modellorganismen bioinformatisch nach Orthologen von SMN und seinen Komplexpartnern durchsucht. Es zeigte sich, dass SMN und Gemin2 die Kernkomponenten des Komplexes darstellen. Von diesen ausgehend kamen weitere Komponenten im Laufe der Evolution hinzu und zwar blockweise, wie es ihrer physischen Assoziation im humanen Komplex entspricht. Um diese Befunde einer biochemischen Überprüfung zu unterziehen, wurde ein neues Affinitätsepitop, das TagIt-Epitop, entwickelt. Nach stabiler Transfektion von Drosophila Schneider2-Zellen konnte das Fusionsprotein effizient exprimiert und der Drosophila-SMN-Komplex nativ aufgereinigt werden. Die massenspektrometrische Untersuchung des Komplexes zeigte, dass SMN und Gemin2 seine einzigen stöchiometrischen Komponenten sind. Dies ist in eindrucksvoller Übereinstimmung mit den bioinformatischen Daten. Der aufgereinigte Komplex lagert in vitro Sm-Proteine mit der entsprechenden UsnRNA zum UsnRNP-core-Komplex zusammen. Diese Ergebnisse ließen sich nach rekombinanter Rekonstitution des SMN/Gemin2-Dimers rekapitulieren. Dabei zeigte sich, dass der SMN-Komplex die unkoordinierte Bindung der Sm-Proteine an „falsche“ RNAs verhindert. Folglich genügen SMN und Gemin2 zur Zusammenlagerung des Sm-core-Komplexes, während die übrigen Gemine weitere Funktionen im Kontext der UsnRNP-Biogenese spielen könnten. Aus evolutionsbiologischer Sichtweise ist der SMN-Komplex aus Drosophila ein eindrückliches Beispiel, wie die Vereinfachung eines biochemischen Prozesses zur Kompaktierung des Genoms beitragen kann.In vertebrates, assembly of spliceosomal UsnRNPs is mediated by the SMN-complex, a macromolecular entity composed of the proteins SMN and Gemins 2-8. In this study, the evolution of this machinery has been investigated using complete genome assemblies of multiple model organisms. The SMN-complex has gained complexity in evolution by a block-wise addition of Gemins onto an ancestral core complex composed of SMN and Gemin2. In contrast to this overall evolutionary trend to higher complexity in metazoans, orthologs of most Gemins are missing in dipterans. In order to challenge these findings by biochemical means, I have developed a novel affinity epitope suitable for use in transfected Drosophila Schneider2-cells. Using protein mass spectrometry, the composition of the Drosophila SMN-complex has been determined. In accordance with the bioinformatic data, it consists of the core components SMN and Gemin2 only. Purified complex mediates assembly of UsnRNP core complexes in a manner very similar to its vertebrate counterpart. These results were recapitulated after recombinant reconstitution of the dSMN/dGemin2-dimer, demonstrating that the Drosophila complex also prevents mis-assembly of Smproteins onto non-target RNAs. Hence, only a minority of Gemins is required for the assembly reaction per se, whereas others may serve additional functions in the context of UsnRNP biogenesis. From a more general point of view, the evolution of the SMN-complex is an interesting example of how the simplification of a biochemical process contributes to genome compaction
The sucbcellular distribution of the regulatory protein RS1 in renal epithelial cells
Diese Arbeit bedient sich der Immunfluoreszenzmikroskopie, um die intrazelluläre Lokalisation des mit der Plasmamembran assoziierten Regulatorproteins RS1 und eines seiner Zielproteine, des Natrium-D-Glucose-Kotransporters SGLT1, in Zellkulturmodellen des Nierenepithels (LLC-PK1- und HEK293-Zellen) zu untersuchen. Zwei polyklonale Antikörper gegen das RS1-Protein des Schweins (pRS1) wurden dafür erzeugt. In Untersuchungen am konfokalen Laser-Scanning-Mikroskop fand sich pRS1 an der Plasmamembran, im Zellkern, intrazellulär an Vesikeln sowie an einem perinukleären Kompartiment. Die Lokalisation des Proteins im Kern von LLC-PK1-Zellen nahm mit zunehmender Differenzierung der Zellen ab, pRS1 wurde in differenzierten Zellen lediglich im perinukleären Kompartiment gefunden. Dieses wurde in Kolokalisationsstudien als trans-Golgi-Netzwerk (TGN) identifiziert und dort eine Kolokalisation von pRS1 mit Clathrin und Dynamin nachgewiesen. Durch Behandlung der Zellen mit Brefeldin A wurde der Verlust von pRS1 vom TGN induziert. SGLT1 wurde überwiegend in Endosomen nachgewiesen, die entlang von Microtubuli organisiert waren. Auch im trans-Golgi-Netzwerk wurde die Anwesenheit von SGLT1 gezeigt. pSGLT1 kolokalisierte dort mit Dynamin aber nicht mit Clathrin. Es wurde demonstriert, dass experimentelle Hemmung der Proteasoms die Menge an pRS1 drastisch erhöht und gegenläufig die des Natrium-D-Glucose-Kotransporter (pSGLT1) abnimmt. Die gewonnenen Daten wurden in einem hypothetischen Modell zusammengefasst, das die gezeigten Ergebnisse mit früher gewonnenen funktionellen Experimente zu einem schlüssigen Konzept zusammenführt.RS1 is a negative regulator of solute transporters such as the Na+-D-glucose cotransporter SGLT1 on the transcriptional and posttranscriptional level. RS1 has been shown to reduce SGLT1-mediated substrate uptake upon coexpression in Xenopus oocytes. This effect is paralleled by decreased membrane surface area and can be counteracted by coexpressed dominant negative dynamin. In this study, I used immunofluorescence microscopy to determine the subcellular distribution of RS1 and SGLT1 in two renal epithelial cell lines (HEK293, LLC-PK1) that express RS1 and SGLT1 endogenously. I found that RS1 was present i) at the plasma membrane, ii) within the nucleus, iii) in small vesicles and iv) at the trans-Golgi network (TGN). At the TGN, RS1 was colocalized with clathrin and dynamin. Incubation of cells with brefeldin A abolished the association of RS1 with the TGN. SGLT1 was likewise present at the TGN although the majority of SGLT1 resided in elongated endosomes. The presence of both RS1 and SGLT1 at the TGN suggests that their functional interaction may involve adaptor proteins such as the Golgi localized, gamma-ear-containing, Arf binding (GGA) proteins. Indeed, RS1 contains a unique acidic cluster dileucine motif on its ubiquitin binding associated (UBA) domain, which we found by 3D modeling to be exposed to the surface of RS1. Taken together with previous data, this study leads to a testable model of RS1 function on the posttranscriptional level
A Micellar Mitotane Formulation with High Drug Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D in Vitro Tumor Models.
Adrenocortical carcinoma (ACC) is a rare tumor and prognosis is overall poor but heterogeneous. Mitotane (MT) has been used for treatment of ACC for decades, either alone or in combination with cytotoxic chemotherapy. Even at doses up to 6 g per day, more than half of the patients do not achieve targeted plasma concentration (14-20 mg/L) even after many months of treatment which is caused by low water solubility and unfavorable pharmacokinetic properties such as poor bioavailability and high volume of distribution of MT. The clinical need and previously reported extraordinary high drug loading of poly(2-methyl-2-oxazoline)-block-poly(2-butyl-2-oxazoline)-block-poly(2-methyl-2-oxazoline) (A-pBuOx-A) based micelles for paclitaxel (PTX), led us to develop MT loaded micelles which may enable an injectable formulation. We successfully solubilized up to 6 g/L of MT in an aqueous formulation. The MT loaded nanoformulations were characterized by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and powder X-ray
diffraction (XRD), confirmed the amorphous nature of drug in the formulations. The polymer itself did not show cytotoxicity in adrenal and liver cell lines. By using the ACC model cell line NCI-H295 both in monolayers and tumor cell spheroids, we demonstrated micellar MT to exhibit comparable efficacy to its ethanol solution. We postulate that this formulation would be suitable for i.v. application and more rapid attainment of therapeutic plasma concentrations. In conclusion, we consider our micellar formulation a promising tool to alleviate major drawbacks of current MT treatment while retaining bioactivity towards ACC in vitro.</p
Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry:utility for diagnosis of dopamine-producing metastatic phaeochromocytoma
Background Measurements of plasma normetanephrine (NMN) and metanephrine (MN) provide a sensitive test for diagnosis of phaeochromocytomas and paragangliomas (PPGLs), but do not allow detection of dopamine-producing tumours. Here we introduce a novel mass spectrometric based method coupled to ultraperformance liquid chromatography (LC-MS/MS) for measuring NMN, MN and 3-methoxytyramine (MTY), the O-methylated metabolite of dopamine. Methods Specific collision-induced fragment ions assessed by multireaction monitoring transitions were used for identification, with quantification according to signal intensities of analytes relative to stable isotope labelled internal standards. Results for solid-phase extracted samples from 196 subjects analysed by LC-MS/MS were compared with those analysed by liquid chromatography with electrochemical detection (LC-ECD). Concentration ranges in 125 volunteers were compared with those from 63 patients with PPGLs, including 14 with metastatic disease. Results The LC-MS/MS method showed linearity over four orders of magnitude with analytical sensitivity sufficient to measure to 0.02 nmol/L. Intra- and inter-assay coefficients of variation ranged from 2.8% to 13.5%. NMN and MN were respectively measured 17% and 10% higher and MTY 26% lower by LC-MS/MS than by LC-ECD. Medians and ranges for 3-methoxytramine, NMN and MN were respectively 0.08 (0.03-0.13), 0.35 (0.13-0.95) and 0.15 (0.07-0.33) nmol/L in volunteers. Among patients with PPGLs, plasma methoxytyramine was six-fold higher in patients with than without metastastases (1.09 versus 0.19 nmol/L) and in three patients was the only metabolite increased. Conclusions The LC-MS/MS method enables accurate, selective and sensitive measurements of catecholamine O-methylated metabolites that should be particularly useful for screening and management of dopamine-producing metastatic PPGLs. </jats:sec
SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?
Targeting molecular alterations as an effective treatment for isocitrate dehydrogenasewildtype
glioblastoma (GBM) patients has not yet been established. Sterol-O-Acyl Transferase 1
(SOAT1), a key enzyme in the conversion of endoplasmic reticulum cholesterol to esters for storage in
lipid droplets (LD), serves as a target for the orphan drug mitotane to treat adrenocortical carcinoma.
Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM
and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in
these tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP,
Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as Oil Red O staining. To
a small extent SOAT1 was expressed by tumor cells in both tumor entities. In contrast, strong
expression was observed in glioma-associated macrophages. Triple immunofluorescence labeling
revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively.
Furthermore, a notable difference in the amount of LD between GBM and HGA was observed.
Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and
invasiveness. In addition, the high expression in cells related to neuroinflammation could be beneficial
for a concomitant suppression of protumoral microglia/macrophages
SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?
Targeting molecular alterations as an effective treatment for isocitrate dehydrogenasewildtype
glioblastoma (GBM) patients has not yet been established. Sterol-O-Acyl Transferase 1
(SOAT1), a key enzyme in the conversion of endoplasmic reticulum cholesterol to esters for storage in
lipid droplets (LD), serves as a target for the orphan drug mitotane to treat adrenocortical carcinoma.
Inhibition of SOAT1 also suppresses GBM growth. Here, we refined SOAT1-expression in GBM
and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), and assessed the distribution of LD in
these tumors. Twenty-seven GBM and three HGA specimens were evaluated by multiple GFAP,
Iba1, IDH1 R132H, and SOAT1 immunofluorescence labeling as well as Oil Red O staining. To
a small extent SOAT1 was expressed by tumor cells in both tumor entities. In contrast, strong
expression was observed in glioma-associated macrophages. Triple immunofluorescence labeling
revealed, for the first time, evidence for SOAT1 colocalization with Iba1 and IDH1 R132H, respectively.
Furthermore, a notable difference in the amount of LD between GBM and HGA was observed.
Therefore, SOAT1 suppression might be a therapeutic option to target GBM and HGA growth and
invasiveness. In addition, the high expression in cells related to neuroinflammation could be beneficial
for a concomitant suppression of protumoral microglia/macrophages
Predictive value of F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib
Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We
aimed to assess the role of metabolic imaging using 2-deoxy-2-(F)fluoro-D-glucose (F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment.
Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline F-FDG PET/CT prior to and 3 months after TKI treatment initiation. During follow-up, CT scans were performed every 3 months and analyzed according to Response Evaluation Criteria In Solid Tumors (RECIST). The predictive value for estimating progression-free (PFS) and overall survival (OS) was examined by investigating F-FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET (rearranged during transfection) mutational status, and disease type).
Results: Within a median follow-up of 5.2 years, 9 patients experienced disease progression after a median time interval of 2.1y whereas the remainder had ongoing disease control (n=5 partial response and n=4 stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5y after TKI initiation.
Pre-therapeutic SUVmean >4.0 predicted a significantly shorter PFS (PFS: 1.9y vs. 5.2y; p=0.04). Furthermore, sustained high 18F-FDG uptake at 3 months with a SUVmean>2.8 tended to portend an unfavorable prognosis with a PFS of 1.9y (vs. 3.5y; p=0.3). Prolonged CEA doubling times were significantly correlated with longer PFS (r=0.7) and OS (r=0.76, p<0.01, respectively). None of the other clinical parameters had prognostic significance.
Conclusions: Pre-therapeutic F-FDG PET/CT holds prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. Low tumor metabolism of SUVmean < 4.0 prior to treatment predicts longer progression-free survival